Phospho-RARA (S77) Antibody

1. Semiquantitative and quantitative analyses of the markers RARA and CRABP2 indicate their potential as biomarkers for tumor progression and their participation in nephroblastoma tumorigenesis PMID:29378601
2. The level of RARalpha gene expression as a potential prognostic factor in the pathogenesis of multiple myeloma. PMID:29119395
3. The data demonstrate that RARalpha drives integrin beta7-dependent adhesion and CCR9-mediated chemotaxis in CTCL cells. PMID:28370539
4. Silencing of PML-RAR and RARalpha2 results in similar increases in the constitutive expression of several granulocytic differentiation markers. PMID:27419624
5. RARA drives cyclin-dependent kinase expression, G1-S transition, and cell growth in T-cell lymphoma. PMID:28412739
6. Demonstrate that RARalpha was frequently elevated in gastric carcinoma and exerted oncogenic properties via positive feedback loop of IL-1beta/Akt/RARalpha/Akt signaling. PMID:28035062
7. Our findings unveil a novel essential oncogenic activity of PML/RARA in Acute promyelocitic leukemia PMID:27626703
8. Findings reveal a previously unrecognized role of c-Myc as a potential ceRNA for PML/RARalpha in acute promyelocytic leukemia. PMID:27486764
9. RARalpha regulates Arp2/3-mediated actin cytoskeletal dynamics through a non-genomic signaling pathway PMID:26848712
10. It has been shown that the AP-1 family member JunB and retinoic acid receptor alpha (RARa) mediate catalase transcriptional activation and repression, respectively, by controlling chromatin remodeling through a histone deacetylases-dependent mechanism. PMID:27591797
11. Work identifies the TP53 tumor suppressor as a novel target through which NPM1-RARA impacts leukemogenesis. PMID:26754533
12. Dual small interfering RNA (siRNA) silencing of RARalpha and RARgamma reversed RA blockade of P4-induced CK5. Using promoter deletion analysis, we identified a region 1.1 kb upstream of the CK5 transcriptional start site that is necessary for P4 activation and contains a putative progesterone response element (PRE PMID:28692043
13. High RARA expression is associated with acute myeloid leukemia. PMID:28416638
14. Data suggest that the binding of Z-10 to RXRalpha inhibited the interaction of RXRalpha with PML-RARalpha, leading to Z-10's selective induction of PML-RARalpha degradation. PMID:28129653
15. PML-RARa bcr1 fusion is not responsible for colorectal tumor development. PMID:22167334
16. overexpression of NLS-RARalpha promoted the proliferation of APL cells and inhibited their differentiation via the PI3K/AKT signaling pathway. PMID:27840989
17. r study demonstrated that ATRA cound promote differentiation while inhibit proliferation of acute promyelocytic leukemia NB4 cells via activating p38a protein after recruiting p38a-combinded NLS-RARa, while NLS-RARa could inhibit the effects of ATRA in the process. PMID:27499693
18. Low expression of RARalpha was independently associated with worse progression-free survival following platinum-based chemotherapy of advanced Non-small cell lung cancer. PMID:27306217
19. The classical counterpart of RARalpha, retinoid X receptor alpha (RXRalpha), was down-regulated in both cytoplasm and nucleus of A549 cells upon atRA addition. PMID:26818829
20. RAI1 polymorphisms rs4925102 and rs9907986 are predicted to disrupt the binding of retinoic acid RXR-RAR receptors and the transcription factor DEAF1, respectively, in Smith-Magenis and Potocki-Lupski syndromes patients. PMID:26743651
21. Data suggest that hematopoietically expressed homeobox protein (HHEX) downmodulation by promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein (PML-RARalpha) is a key event during acute promyelocytic leukemia (APL) pathogenesis. PMID:27052408
22. ATRA dramatically down regulated RARalpha protein levels and led to more DNA damage and ultimately resulted in the synergism of these two agents PMID:26728137
23. NPM-RAR binding to TRADD selectively inhibits caspase activation, while allowing activation of NFkappaB and JNK PMID:25791120
24. Suggest a novel role of PCGF2 in arsenic trioxide-mediated degradation of PML-RARA that PCGF2 might act as a negative regulator of UBE2I via direct interaction. PMID:27030546
25. down-regulation of the level of RAR alpha leads to increased expression of VDR in acute myeloid leukemia. PMID:26969398
26. Methylated arsenic metabolites bind to PML protein but do not induce cellular differentiation and PML-RARalpha protein degradation in acute promyelocytic leukemia. PMID:26213848
27. Novel insight into the functional difference of acquired mutations of PML-RARA both in vitro and in the clinical setting. PMID:26537301
28. our findings challenge the predominant model in the field and we propose that PML/RARA initiates leukemia by subtly shifting cell fate decisions within the promyelocyte compartment. PMID:26088929
29. RARalpha might be involved in the pathogenesis of varicocele as its expression is reduced in pathologic samples. PMID:24992177
30. The PML-region mutations were associated with response to Arsenic trioxide-based therapy (P < 0.0001), number of relapses (P = 0.001), and early relapse (P = 0.013)in acute promyelocytic leukemia patients. PMID:26294332
31. Data show that the tumor suppressor RASSF1A is a direct target of the PML/RARalpha-regulated microRNAs miR-181a/b cluster. PMID:26041820
32. These results suggest that overexpression of RARA enhances malignant transformation during mammary tumorigenesis. PMID:25300573
33. E2F1 is found to downregulate retinoic acid receptor alpha (RARalpha), a key factor determines the effectiveness of all-trans retinoic acid. PMID:24608861
34. bortezomib impairs the UPS that controls normal protein homeostasis by causing excessive accumulation of PML-RARA augmenting ER stress and leading to acute promyelocytic leukemia cell death PMID:26026090
35. CDKN2D repression by PML/RARalpha disrupts both cell proliferation and differentiation in the pathogenesis of acute promyelocytic leukemia. PMID:25275592
36. These results indicate that NPM-RAR, not RAR-NPM, is the prime mediator of myeloid differentiation arrest in t(5;17) APL. PMID:23927396
37. This study identifies a novel mechanism through which NPM-RAR affects leukemogenesis PMID:25033841
38. Data indicate that retinoic acid receptor (RAR) is crucial for regulating sodium taurocholate cotransporting polypeptide (NTCP) expression that determines permissiveness to hepatitis B virus (HBV) infection. PMID:25550158
39. Human miR-138 promotes tau phosphorylation by directly targeting the RARA and the associated GSK-3beta pathway. PMID:25680531
40. Down-regulation of NLS-RARalpha expression inhibited the proliferation and induced the differentiation of HL-60 cells. On the contrary, over-expression of NLS-RARa promoted proliferation and reduced the ATRA-induced differentiation of HL-60 cells. PMID:24516348
41. PML-RARalpha cooperates with HIF-1alpha to activate a pro-leukemogenic program. PMID:24711541
42. Results show that UTX interacts with the retinoic acid receptor alpha (RARalpha) and this interaction is essential for proper differentiation of leukemic U937 cells in response to retinoic acid. PMID:25071154
43. SUMO-1 modification of RARA is a potent mechanism for balancing proliferation and differentiation by controlling the stability of RARA in cancer cells. PMID:24819975
44. The current status of knowledge indicates that there might be inter- or overlapping actions between PPARg and RARs, and there might be an association of PPARg/RARs(RARa, RARb, and RARg) with renal diseases PMID:24050824
45. PML/RARalpha suppresses PU.1-dependent activation of the proteasome immunosubunits in acute promyelocytic leukemia. PMID:23770850
46. The presence of a mutation in the arsenic-binding domain of PML-RARA led to arsenic resistance in patients with acute promyelocytic leukemia. PMID:24806185
47. The objective was to describe the frequency of molecular subtypes of PML/RARalpha in patients with acute promyelocytic leukemia (APL) and their distribution according to risk of recurrence and cytomorphology PMID:23612809
48. provide evidence for the existence of a functional ternary complex containing TDG, CBP and activated RARalpha PMID:24394593
49. Differences in RAR and RXR subtype mRNA expression patterns in various PTCs may contribute to the immunochemistry data available, and may thus find exploitation in clinical oncology, particularly in the differential diagnosis of thyroid neoplasms. PMID:23969901
50. The tumor suppressor gene DAPK2 is induced by the myeloid transcription factors PU.1 and C/EBPalpha during granulocytic differentiation but repressed by PML-RARalpha in APL. PMID:24038216

Show More

Hide All

HGNC: 9864

UNIGENE: Hs.654583

KEGG: hsa:5914

STRING: 9606.ENSP00000254066

OMIM: 180240